Join the club for FREE to access the whole archive and other member benefits.

Benedict Albensi

Principal Investigator, Chair & Professor, Pharmaceutical Sciences, Mitrix Bio

Dr. Benedict C. Albensi, Ph.D., BCMAS, CRQM is a Professor of Pharmacology and Therapeutics at the Max Rady College of Medicine – University of Manitoba and a Principal Investigator and the Everett Endowment Fund Chair for Alzheimer’s Research at the St. Boniface Hospital Research Centre (since 2005). He is best known for his work with factors involved in ageing, cognition, and Alzheimer’s disease (AD), such as nuclear factor kappa B (NF-kB), a mediator of inflammation and a required molecule for memory. He obtained his Ph.D. in Neuroscience from the University of Utah’s Medical School in 1995.

He was awarded a Postdoctoral Fellowship at Georgetown University in Washington, DC, working with Drs. Faden and Pekar, where he developed MRI methods for investigating head trauma and cognition. He then went on to work as a Postdoctoral Scholar with Dr. Mark Mattson, an internationally recognized leader in neurodegenerative research, at the Sanders-Brown Center on Aging – University of Kentucky where he was the first to show NF-kB is required for synaptic plasticity in mammals. 

He has been ranked in the top 1% worldwide by Expertscape.com for his number of publications from 2010-2020 in 7 areas including Alzheimer Disease (0.48%), neurocognitive disorders (0.76%), tauopathies (0.98%), dementia (0.85%), NF-kappa B (0.42%), memory (68%) & energy metabolism (0.68%).


Visit website: http://www.sbrc.ca/albensi/

 benedict-albensi

 balbensi

See also: Company Mitrix Bio - California based start-up company

Details last updated 28-Jul-2022

Benedict Albensi News

Mitochondrial transplants show efficacy in achieving longevity in humans

Lifespan.io (LEAF) - 19-Jul-2022

Mitochondrial transplant raise energetics of the body, so it can withstand longevity treatments

Read more...